Health and Healthcare

La Jolla Pharmaceutical Shares Surge on Positive Trial Results

La Jolla Pharmaceutical Co. (NASDAQ: LJPC) shares surged after the micro-cap biotech said late Monday that its study for a chronic kidney disease treatment showed a statistically significant improvement.

The company said the randomized, placebo-controlled Phase II trial of GCS-100 in chronic kidney disease met its primary efficacy endpoint of a statistically significant improvement in kidney function. Key secondary endpoints were also met.

La Jolla Pharmaceutical CEO George Tidmarsh said:

We want to thank the patients who volunteered for this study and our excellent group of investigators for their hard work completing this Phase 2 trial in a timely fashion. We are obviously delighted with the results. … We hope to use these results as a platform for further investigation not only in chronic kidney disease but also in other diseases where tissue fibrosis plays a central role.

Chronic kidney disease reportedly affects 14% of Americans, or around 49 million people. GCS-100 is a high molecular weight, complex polysaccharide that inhibits galectin-3, a molecule suspected of playing a central role in tissue fibrosis. GCS-100 also has been shown to be therapeutically active in preclinical models of other diseases where tissue fibrosis plays a central role, such as nonalcoholic steatohepatitis.

La Jolla Pharmaceutical shares were up more than 58% in premarket trading to $17.27. The 52-week range had been $3.00 to $12.00.

Get Ready To Retire (Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Get started right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.